Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 4
2004 8
2005 12
2006 23
2007 25
2008 24
2009 23
2010 18
2011 31
2012 24
2013 36
2014 46
2015 39
2016 32
2017 49
2018 34
2019 43
2020 32
2021 42
2022 38
2023 41
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

572 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean sangmyung kim (3 results)?
Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers.
Lowery FJ, Krishna S, Yossef R, Parikh NB, Chatani PD, Zacharakis N, Parkhurst MR, Levin N, Sindiri S, Sachs A, Hitscherich KJ, Yu Z, Vale NR, Lu YC, Zheng Z, Jia L, Gartner JJ, Hill VK, Copeland AR, Nah SK, Masi RV, Gasmi B, Kivitz S, Paria BC, Florentin M, Kim SP, Hanada KI, Li YF, Ngo LT, Ray S, Shindorf ML, Levi ST, Shepherd R, Toy C, Parikh AY, Prickett TD, Kelly MC, Beyer R, Goff SL, Yang JC, Robbins PF, Rosenberg SA. Lowery FJ, et al. Among authors: kim sp. Science. 2022 Feb 25;375(6583):877-884. doi: 10.1126/science.abl5447. Epub 2022 Feb 3. Science. 2022. PMID: 35113651 Free PMC article.
Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors.
Kim SP, Vale NR, Zacharakis N, Krishna S, Yu Z, Gasmi B, Gartner JJ, Sindiri S, Malekzadeh P, Deniger DC, Lowery FJ, Parkhurst MR, Ngo LT, Ray S, Li YF, Hill V, Florentin M, Masi RV, Paria BC, Levin N, Bera A, Hedges EA, Choi A, Chatani PD, Parikh AY, Levi S, Seitter S, Lu YC, Zheng Z, Prickett TD, Jia L, Hernandez JM, Hoang CD, Robbins PF, Goff SL, Sherry RM, Yang JC, Rosenberg SA. Kim SP, et al. Cancer Immunol Res. 2022 Aug 3;10(8):932-946. doi: 10.1158/2326-6066.CIR-22-0040. Cancer Immunol Res. 2022. PMID: 35749374 Free PMC article.
Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial.
Koo BK, Kang J, Park KW, Rhee TM, Yang HM, Won KB, Rha SW, Bae JW, Lee NH, Hur SH, Yoon J, Park TH, Kim BS, Lim SW, Cho YH, Jeon DW, Kim SH, Han JK, Shin ES, Kim HS; HOST-EXAM investigators. Koo BK, et al. Lancet. 2021 Jun 26;397(10293):2487-2496. doi: 10.1016/S0140-6736(21)01063-1. Epub 2021 May 16. Lancet. 2021. PMID: 34010616 Clinical Trial.
U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies.
Smith MA, Choudhary GS, Pellagatti A, Choi K, Bolanos LC, Bhagat TD, Gordon-Mitchell S, Von Ahrens D, Pradhan K, Steeples V, Kim S, Steidl U, Walter M, Fraser IDC, Kulkarni A, Salomonis N, Komurov K, Boultwood J, Verma A, Starczynowski DT. Smith MA, et al. Among authors: kim s. Nat Cell Biol. 2019 May;21(5):640-650. doi: 10.1038/s41556-019-0314-5. Epub 2019 Apr 22. Nat Cell Biol. 2019. PMID: 31011167 Free PMC article.
Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes.
Zacharakis N, Huq LM, Seitter SJ, Kim SP, Gartner JJ, Sindiri S, Hill VK, Li YF, Paria BC, Ray S, Gasmi B, Lee CC, Prickett TD, Parkhurst MR, Robbins PF, Langhan MM, Shelton TE, Parikh AY, Levi ST, Hernandez JM, Hoang CD, Sherry RM, Yang JC, Feldman SA, Goff SL, Rosenberg SA. Zacharakis N, et al. Among authors: kim sp. J Clin Oncol. 2022 Jun 1;40(16):1741-1754. doi: 10.1200/JCO.21.02170. Epub 2022 Feb 1. J Clin Oncol. 2022. PMID: 35104158 Free PMC article. Clinical Trial.
Comparison of 3- to 6-Month Versus 12-Month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-Eluting Stents With Ultrathin Struts: The HOST-IDEA Randomized Clinical Trial.
Han JK, Hwang D, Yang S, Park SH, Kang J, Yang HM, Park KW, Kang HJ, Koo BK, Hur SH, Kim W, Kim SY, Park SH, Han SH, Kim SH, Shin S, Kim YH, Park K, Lee N, Lee SJ, Kim JW, Kim HS. Han JK, et al. Circulation. 2023 May 2;147(18):1358-1368. doi: 10.1161/CIRCULATIONAHA.123.064264. Epub 2023 Mar 5. Circulation. 2023. PMID: 36871230 Clinical Trial.
In reply.
Cannesson M, Rinehart J, Kim SH. Cannesson M, et al. Anesthesiology. 2015 Jan;122(1):209-10. doi: 10.1097/ALN.0000000000000486. Anesthesiology. 2015. PMID: 25611657 Free article. No abstract available.
A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia.
Kim MC, Ahn Y, Kim MH, Kim SY, Hong TJ, Rhee MY, Kim SH, Hong SJ, Kim H, Kim W, Chae IH, Kang DH, Kim BK, Kim HS. Kim MC, et al. Am J Cardiovasc Drugs. 2023 Jul;23(4):441-454. doi: 10.1007/s40256-023-00590-9. Epub 2023 Jul 3. Am J Cardiovasc Drugs. 2023. PMID: 37395974 Free PMC article. Clinical Trial.
Pulse Wave Velocity in Atherosclerosis.
Kim HL, Kim SH. Kim HL, et al. Front Cardiovasc Med. 2019 Apr 9;6:41. doi: 10.3389/fcvm.2019.00041. eCollection 2019. Front Cardiovasc Med. 2019. PMID: 31024934 Free PMC article. Review.
Pancreatic Tumor-Targeting Stemsome Therapeutics.
Park JY, Park JY, Jeong YG, Park JH, Park YH, Kim SH, Khang D. Park JY, et al. Adv Mater. 2023 Jul;35(30):e2300934. doi: 10.1002/adma.202300934. Epub 2023 Jun 11. Adv Mater. 2023. PMID: 37114740
572 results